<DOC>
	<DOC>NCT01001572</DOC>
	<brief_summary>This study assessed the efficacy and safety of the valsartan/amlodipine 160/5 mg single-pill combination in patients with uncomplicated essential hypertension not adequately controlled (MSDBP ≥90 mmHg and &lt;110 mmHg) on valsartan 160 mg alone.</brief_summary>
	<brief_title>Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine, Valsartan Drug Combination</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Patients must give written informed consent Male or female ages 18 or older and less than 86 years Diagnosed as having essential diastolic hypertension, as follows: Visit 2/Singleblind runin entry, all participants MUST have a MSDBP ≥ 95 mmHg and &lt; 100 mmHg At Visit 3/Core doubleblind treatment period entry, all patients MUST have a MSDBP &gt;=90 mmHg and &lt;110 mmHg Severe hypertension Evidence of secondary form of hypertension (coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's disease, pheochromocytoma or polycystic kidney disease ) Malignant hypertension Administration of any agent indicated for the treatment of hypertension after Visit 1 Known moderate or malignant retinopathy. Known or suspected contraindications, including history of allergy or hypersensitivity to Angiotensin II Receptor Blockers (ARBs), Calcium Channel Blockers (CCBs), or to drugs with similar chemical structures History of hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack, myocardial infarction or all types of revascularization, angina pectoris of any type, including unstable angina History of heart failure Grade IIIV according to New York Heart Association (NYHA) classification Second of third degree heart block regardless of the use of a pacemaker, concomitant potentially lifethreatening arrhythmia or symptomatic arrhythmia Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Blood pressure</keyword>
	<keyword>hypertension</keyword>
	<keyword>Exforge</keyword>
	<keyword>valsartan/amlodipine</keyword>
</DOC>